Swiss researchers report on metastasis switch
Researchers from Paul Scherrer Institute in Villingen, Switzerland, and Hoffmann La-Roche AG report in Cell they have solved the structure of a target relevant in metastasis.
Preclinical antibody stops rheumatoid arthritis
An antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models.
Nabriva receives FDA approval for novel antibiotics
Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action to treat community-acquired bacterial pneumonia.
Araris Biotech AG kicks-off with CHF2.5m seed financing
Zurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting.
PharmaMar moves ahead with NDA for Zepsyre
The FDA has given the go-ahead to PharmaMars proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.
Swedish researchers find new pain organ
Researchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts.
Researchers unravel potential cancer target
British researchers have found out what’s going wrong with chromosome segregation in some cancers.
Pharming licenses orphan drug from Novartis
Pharming NV has paid 17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS
New stem cell population may help repair teeth
Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.
Bayer bags iPSC specialist BlueRock Therapeutics
Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.